Skip to content
Screener

Reported November 12, 2026 · After market close

EPS-$0.12Beat by $0.02
EPS estimate-$0.15
“Relmada has made significant progress in advancing the NDV-01 CMC program and remains on track to submit the NDV-01 IND by year-end 2026. Furthermore, we have established a manufacturing plan to provide uninterrupted clinical supply through the completion of the Phase 3 SPECTRUM program”
Sergio Traversa

Next report

Date not yet announced

FAQ

When did Relmada Therapeutics, Inc. report Q3 2026 earnings?
Relmada Therapeutics, Inc. (RLMD) reported Q3 2026 earnings on November 12, 2026 after market close.
What were Relmada Therapeutics, Inc.'s Q3 2026 revenue and EPS?
Relmada Therapeutics, Inc. reported eps of $-0.12 for Q3 2026.
Did Relmada Therapeutics, Inc. beat estimates in Q3 2026?
EPS beat the consensus estimate of $-0.14 by $0.02.
How did Relmada Therapeutics, Inc.'s Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 60.0% from $-0.30.
Where can I find Relmada Therapeutics, Inc.'s Q3 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-118933) and the 10-Q periodic report (0001213900-26-118916) directly on SEC EDGAR. The filing index links above go to sec.gov.